In many mammalian cell types, engagement of the TRAIL/Apo2L death receptors DR4 and DR5 alters mitochondrial physiology, thereby promoting the release of pro-apoptotic proteins normally contained within this organelle. A contemporary view of this process is that in so-called type II cells death receptor-activated caspase-8 cleaves the Bcl-2 family member Bid, which generates a truncated Bid fragment that collaborates with Bax, another Bcl-2 relative, to promote the release of mitochondrial factors necessary for activation of executioner caspases and apoptosis. Here we show that in some type II cells caspase-2 is necessary for optimal TRAIL-mediated cleavage of Bid. Down-regulation of caspase-2 using RNA interference significantly inhibited TRAIL-induced apoptosis. Analysis of the TRAIL proteolytic cascade following gene silencing of specific pathway components revealed that caspase-2 is necessary for efficient cleavage of Bid; however, caspase-2 proteolytic processing, which occurs downstream of Bax, is not necessary for its role in Bid cleavage.
5). In type II cells, the two prototypical pathways, extrinsic (death receptor) and intrinsic (mitochondrial), are interconnected by caspase-8-mediated cleavage of the pro-apoptotic Bcl-2 family member Bid, producing a truncated Bid (tBid) fragment that promotes the mitochondrial release of the proapoptotic factors cytochrome c and Smac (6) . Once released into the cytoplasm, cytochrome c associates with Apaf-1 and procaspase-9 to form the "apoptosome," which leads to the activation of pro-caspase-9 and subsequent activation of effector caspases such as caspase-3 and caspase-7. In parallel, mitochondrial-released Smac binds to members of the inhibitor of apoptosis (IAP) protein family and thereby prevents IAP inhibition of caspase-3, -7, and -9 (7) (8) (9) .
Historically, the placement of caspase-2 in these prototypical cell death pathways has been lacking (10) . Moreover, the absence of a severe phenotype in caspase-2-deficient mice (11) has lead to speculation that this enzyme does not play as significant a role in apoptosis as other family members. Nevertheless, several research groups (12) (13) (14) have recently shown that caspase-2 induces apoptosis by releasing pro-apoptotic proteins from mitochondria and that it is essential for cytotoxic stressinduced apoptosis in selected human cell lines, whereas other investigators (15) have suggested that activation of this cell death enzyme occurs downstream of the mitochondria. Thus, the placement of caspase-2 in apoptosis pathways is controversial, and the exact function, mode of activation, and regulation of caspase-2 remain unknown.
To further elucidate the TRAIL-induced apoptosis pathway, we designed small interfering RNAs (siRNAs) toward many genes that reportedly play a role in apoptosis and used them as controls in siRNA library screens (16, 17) . During the development and validation of these siRNAs, we found that silencing caspase-2 expression suppressed TRAIL-induced apoptosis in several cell lines. Using siRNAs that specifically block distinct steps in the TRAIL pathway allowed us to place caspase-2 upstream of Bid cleavage in some cell types. Moreover, we provide evidence that caspase-2 activity but not its proteolytic processing is necessary for its role in Bid cleavage. Thus, for the first time, we reveal the involvement of caspase-2 in TRAILinduced apoptosis and define the localization of caspase-2 within this pathway.
MATERIALS AND METHODS
Reagents-Cell culture reagents were purchased from Invitrogen. Soluble recombinant human TRAIL/Apo2L, composed of residues 114 -281 was purchased from Calbiochem, and all other chemicals (including etoposide and staurosporine) were from Sigma. The DR5-specific agonist antibody was isolated from a functional screen for DR5 receptormediated cell killing. 2 Cell Culture and Cell Lines-The HCT116 human colon adenocarcinoma cell lines, which either contain one intact Bax allele (Baxϩ/Ϫ * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ‡ Present address: Dept. of Molecular Diagnostics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080.
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genotype) or are Bax-deficient (BaxϪ/Ϫ genotype) (18) , were kind gifts of Dr. Bert Vogelstein (Johns Hopkins University School of Medicine, Baltimore, MD). The cells were cultured at 37°C and 5% CO 2 in McCoy's 5A medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 g/ml). The T3M4 human pancreatic cancer cells were kindly provided by Andreas Marti and Hans Graber (University of Bern, Switzerland). HeLa human cervix adenocarcinoma cells were grown in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal bovine serum. siRNA Design and Transfection Protocol-The siRNAs against caspase-2, caspase-8, Bid, and XIAP were designed using three independent selection programs from Dharmacon (Lafayette, CO), Ambion, and Genomics Institute of the Novartis Research Foundation (siRNA Picker), using published standard criteria, and the caspase-2 (cDNA position 94 (siC2-94)) was published by Lassus et al. (12) . The selected sequences were: siCaspase-2, cDNA position 510 (siC2-510): 5Ј-AA-CTTCCAGCTG-GCATATAGG-dTdT-3Ј; siCaspase-8: 5Ј-AA-GGGUCAUGCUCUAUCAG-AU-dTdT-3Ј; siBid: 5Ј-AA-GAAGACAUCAUCCGGAAUA-dTdT-3Ј; and siXIAP: 5Ј-AA-GGAGAUACCGUGCGGUGCU-dTdT-3Ј.
siRNAs were purchased from Dharmacon as double-stranded RNA oligonucleotides and transfected into the respective cell lines using LipofectAMINE 2000 (Invitrogen) at concentrations of 800 ng of siRNA plus 4 l of LipofectAMINE 2000/1 ϫ 10 5 cells/ml in a 6-well plate format with a final volume of 2 ml and reduced accordingly for the 96-well format. siRNA duplexes against luciferase GL3 RNA were used as a control (5Ј-AA-CTTACGCTGAGTACTTCGA-dTdT-3Ј).
Cell Viability Assays-The MTT assay, which is a colorimetric assay based on the ability of viable cells to reduce a soluble yellow tetrazolium salt (MTT) to blue formazan crystals, was used to determine the amount of viable cells after down-regulation of specific genes with the respective siRNAs for 48 h followed by incubation with recombinant human TRAIL, agonistic anti-DR5 antibodies, and etoposide or staurosporine for an additional 24 h. Afterward, MTT dye solution was added for 4 h, the blue crystal product was solubilized overnight at 37°C, and absorbance was measured at 570 nm.
Western Blot Analysis and Antibodies-1 ϫ 10 5 cells/well were seeded in 6-well plates and treated with different siRNAs for 48 h followed by treatment with TRAIL for 1, 3, or 6 h. After the indicated periods of time, cells were washed in ice-cold phosphate-buffered saline and lysed in 1% Triton X-100 containing hypotonic lysis buffer (20 mM HEPES, pH 7.5, 10 mM KCL, 1.5 mM MgCl 2 , 1 mM EDTA, and 1 mM dithiothreitol). For each sample, 40 g of protein was separated under reducing conditions on 10 -20% gradient SDS-polyacrylamide gels. After transfer to nitrocellulose membranes (Schleicher & Schuell), the membranes were incubated for 1 h in 10% nonfat milk powder followed by a 1-h incubation with the following primary antibodies: mouse anticaspase-2 antibody (1:1000, BD Biosciences), rabbit anti-caspase-3 antibody (1:1000, Pharmingen), rabbit anti-caspase-8 antibody (1:1000, Pharmingen), mouse anti-caspase-9 antibody 5B4 (1:1000) and mouse anti-caspase-10 antibody 4C1 (1:1000; MBL International Corp.), and rabbit anti-Bid antibody (1:1000, Pharmingen) or goat anti-actin antibody (1:200, Santa Cruz Biotechnology). Membranes were washed five times with Tris-buffered saline, 0.05% Tween and then incubated with the respective peroxidase-conjugated affinity-purified secondary antibody (1:5000, Bio-Rad) for 30 min. The membranes were washed again five times and developed using enhanced chemiluminescence (ECL, Amersham Biosciences) and exposure to Kodak Biomax films.
Caspase Assays-Caspase-3 and caspase-7 activities were assayed as described previously (4) at 37°C in 40 l of caspase buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 10% sucrose, 1 mM EDTA, 0.1% CHAPS, and 10 mM dithiothreitol) containing 100 M fluorogenic peptide Ac-DEVD-AFC. Activity was measured at the indicated times by the release of AFC from DEVD-AFC using a Molecular Devices fluorometer in the kinetic mode and with the 405-510 filter pair. For the assessment of caspase activity, 20 g of total cell protein (Triton X-100 extracts) was used in 40 l of caspase buffer (containing 100 M DEVD-AFC).
RESULTS

Silencing Caspase-2 Expression with Small Interfering RNAs
Inhibits TRAIL-induced Cell Death-Several siRNAs that previously have been shown to specifically down-regulate their intended targets caspase-8 (17), Bid (17), caspase-2 (12), and XIAP (16) were transiently transfected into HCT116 human colon adenocarcinoma cells to test their ability to suppress or enhance TRAIL-induced reduction in cell viability (Fig. 1, A and B). As would be expected for a type II cell line, siCaspase-8 and siBid protected, whereas siXIAP slightly enhanced, TRAIL-mediated reduction in cell viability. Notably, siCaspase-2 exhibited significant protection against TRAIL-induced cell death. Pretreating HCT116 cells with siCaspase-2 decreased TRAIL-induced apoptosis by at least 30%, whereas silencing caspase-8 or Bid inhibited TRAIL-mediated reduction in cell viability by ϳ80 and 70%, respectively (Fig. 1A ). The differences in magnitude of apoptosis suppression mediated by these siRNAs may reflect their differential efficacies, the protein half-lives of their targets, or the necessity for each of these proteins in the TRAIL pathway in this cell type. Regardless, these data implicate caspase-2 as a component of TRAIL-mediated cell death at least in HCT116 cells.
The siRNA-targeting caspase-2 used in the experiments described above was rigorously characterized by Lassus et al. (12) . Nevertheless, we designed a second siRNA-targeting caspase-2 to further validate our results. These two independent non-overlapping siRNAs were tested for their ability to diminish caspase-2 protein and influence TRAIL-induced apoptosis. Both siRNAs directed toward caspase-2 significantly inhibited TRAIL-induced cell death (Fig. 1C ) and changes in cell morphology such as detachment, nuclear condensation, and production of apoptotic bodies (data not shown), which confirmed our previous results. Moreover, each caspase-2-specific siRNA efficiently silenced caspase-2 protein expression but not the expression of other proteins that were analyzed (Fig. 1 , B and C; data for caspase-9 and -3 not shown). These data indicate that our results are not attributable to siRNA "off-target" effects or an RNA interference-induced interferon response, because two distinct non-overlapping siRNAs against caspase-2 exhibited a similar phenotype compared with control siRNAs and showed a specific down-regulation of caspase-2 among the caspase protein family members assessed.
Reported concerns about nonspecific cytotoxicity with recombinant versions of human TRAIL, particularly with polyhistidine-tagged preparations (19) , prompted us to repeat our experiments with DR5-specific agonistic antibodies (DR5-A). These antibodies bind and activate DR5 but not other tumor necrosis factor receptors including DR4 and the TRAIL decoy receptors DcR1 and DcR2 (20) . Consistent with our previous studies using recombinant TRAIL, siCaspase-2 also suppressed DR5-A-mediated reduction in cell viability (Fig. 1D) .
To further evaluate the functional role of caspase-2 in apoptosis, we tested whether siCaspase-2 would also inhibit other agents that induce cell death. For these studies we used etoposide, a DNA-damaging topoisomerase II inhibitor, and staurosporine, a broad spectrum protein kinase inhibitor. In contrast to TRAIL and DR5-A-induced apoptosis, siRNA-mediated down-regulation of caspase-2, caspase-8, or Bid did not inhibit etoposide-or staurosporine-mediated cell death pathways in HCT116 cells (Fig. 1, E and F) . These results may suggest that caspase-2 functions upstream of the mitochondria in the TRAIL pathway because the TRAIL, staurosporine, and DNA damage cell death pathways reportedly share the mitochondrial release of cytochrome c and the subsequent activation of downstream executioner caspases-3 and -7 but differ in events upstream of the mitochondria (5, 21) . Moreover these data indicate that the reported role of caspase-2 in stress-induced apoptosis (12) is cell-specific.
Inhibitory Effect of siCaspase-2 for TRAIL-induced Apoptosis Is Cell Type-dependent-To determine whether our results were restricted to a single cell line, we expanded our study to include T3M4 human pancreatic cancer cells and HeLa human cervix adenocarcinoma cells. These cell lines were chosen because they were easily transfectable with siRNA oligonucleotides and were sensitive to TRAIL or DR5-A. siCaspase-2 sup-pressed TRAIL-induced cell death in T3M4 cells, again, to a slightly lesser extent than siCaspase-8 or siBid (Fig. 2A) . In contrast to HCT116 and T3M4, HeLa cells did not require caspase-2 for TRAIL-induced apoptosis but were clearly dependent on caspase-8 and Bid (Fig. 2B) . Thus, some but not all type II cells require the presence of caspase-2 for optimal TRAIL-induced cell death.
siRNA Mapping of the TRAIL Cell Death Pathway-Silencing caspase-2 expression not only inhibited TRAIL-mediated reduction in cell viability assays it also suppressed caspase activation, the biochemical hallmark of apoptosis. Transfection of siCaspase-8, siBid, and siCaspase-2 but not control siRNAs inhibited TRAIL-mediated cell rounding and detachment in HCT116 cells (not shown) and caspase activation as measured by hydrolysis of the executioner caspase substrate DEVD-AFC (Fig. 3A) . To define the position of caspase-2 in the TRAIL pathway, however, we examined caspase processing in these cells by Western blot analysis. In cells treated with the control siRNA, complete proteolytic processing of caspase-8 occurred beginning as early as 1 h after the addition of TRAIL (Fig. 3A) . Based on a type II mechanism (5), active caspase-8 in turn cleaves the Bcl-2 family protein Bid. The resulting tBid promotes the mitochondrial release of Smac and cytochrome c. In the cytosol, cytochrome c catalyzes the formation of an Apaf-
FIG. 1. Silencing caspase-2 expression with specific siRNAs inhibits TRAIL-induced cell death.
A, an MTT cell viability assay was used to determine the amount of viable HCT116 cells after down-regulation of caspase-2, caspase-8, Bid, and XIAP with the respective siRNAs for 48 h followed by incubation with recombinant human TRAIL for 24 h. An siRNA against luciferase GL3 (siGL3) was used as a control. B, Western blot analysis of siRNA-mediated silencing of protein expression of caspase-2, caspase-8, Bid, and XIAP with the respective siRNAs. C, comparison of the TRAIL rescue effect of two non-overlapping siRNAs (siC2-94 and siC2-510) against caspase-2 with corresponding Western blot analysis of siCaspase-2 specificity. D, reconfirmation experiments with DR5-specific agonistic antibodies were performed as described in A. E and F, cell viability following down-regulation of caspase-2, caspase-8, and Bid with the respective siRNAs for 48 h was followed by incubation with etoposide (E) and staurosporine (F) for an additional 24 h. Experiments were performed in triplicate, and error bars represent the standard deviation from the mean.
1⅐pro-caspase-9 complex, which facilitates caspase-9 autocatalytic processing and activation. Although active caspase-8 and -9 can directly process caspase-3, complete maturation and activity of caspase-9 and caspase-3 require mitochondrial release of Smac (22), which relieves IAP-mediated inhibition of these enzymes (7). This TRAIL-induced proteolytic cascade was readily observed by Western blot analysis in control siRNAtransfected cells treated with TRAIL (Fig. 3A , mitochondrial release of cytochrome c and Smac not pictured).
Following siRNA-mediated reduction of caspase-8, TRAIL failed to induce Bid cleavage, and subsequent downstream proteolytic events were blocked (Fig. 3A) . siBid treatment allowed caspase-8 activation but prevented the release of mitochondrial factors such as cytochrome c and Smac (data not shown) and caspase-9 processing (Fig. 3A) . In TRAIL-treated cells that were transfected with siBid, active caspase-8 can initially cleave pro-caspase-3 to the p24 form of its large subunit (Fig. 3A) . Complete processing to the active, mature p20 and p17 subunits, however, was blocked because this requires tBid-mediated release of mitochondrial factors, such as Smac (22) . These observations are in accordance with the lack of caspase-3 and -7 activity in TRAIL-treated cells in which caspase-8 or Bid expression was silenced by siRNA (Fig. 3A) and are consistent with numerous reports using a variety of other methods that have ordered or "mapped" the receptormediated type II cell mechanism for activation of executioner caspases (5, 23) Caspase-2 Is Interconnected between Caspase-8 Activation and Bid Cleavage-siRNA-mediated silencing of caspase-2 expression allowed full caspase-8 activation but clearly diminished Bid cleavage and further events that are dependent on tBid, such as caspase-9 activation and complete maturation of caspase-3 (Fig. 3A) . Concordantly, TRAIL-induced enzymatic caspase-3 and -7 activity in siCaspase-2-transfected cells was reduced by ϳ60%, respectively (Fig. 3A) . These data indicate that caspase-2 is required upstream of Bid in the TRAIL pathway. Similar to siCaspase-2-treated cells, cellular exposure to the substrate-based caspase-2 inhibitor Z-VDVAD-fmk suppressed TRAIL-induced Bid cleavage without influencing TRAIL-induced caspase-8 autocatalytic processing (Fig. 3B) . Although data obtained using these peptidyl-based caspase inhibitors should be interpreted with caution because they lack absolute specificity, these results suggest that caspase-2 activity, rather than its presence alone, is required for Bid processing. Combined, these data place caspase-2 below caspase-8 but upstream of Bid cleavage in the TRAIL apoptosis pathway.
In accordance with the role of caspase-2 proposed above, caspase-2 cleavage was not detected in TRAIL-treated cells containing siRNAs targeting caspase-8 (Fig. 3A) . Caspase-2 cleavage, however, was also suppressed in Bid-silenced cells (Fig. 3A) , which points to the proteolytic processing of caspase-2 occurring downstream of Bid cleavage, whereas our data indicate that caspase-2 functions prior to Bid cleavage. This could occur if proteolytic processing of caspase-2 were not required for its activation, which has been reported for other caspases (2, 24) . To examine this idea, we used Bax-deficient HCT116 cells (HCT116 BaxϪ/Ϫ) (18) . Because tBid requires association with Bax for mitochondrial release of Smac and cytochrome c and the subsequent activation of downstream executioner caspases, HCT116 BaxϪ/Ϫ cells are TRAIL-resistant (22, 25) . Consistent with those data, we found that Bax deficiency had little affect on TRAIL-induced caspase-8 processing and subsequent cleavage of Bid but clearly suppressed caspase-9 processing (Fig. 4) and the maturation and activity of caspase-3 (data not shown), compared with the TRAIL-treated parental HCT116 Baxϩ/Ϫ cell line (Fig. 4) . Similar to siBidtransfected HCT116 Baxϩ/Ϫ cells treated with TRAIL (Fig.  3A) , caspase-2 processing was suppressed in TRAIL-treated HCT116 BaxϪ/Ϫ cells (Fig. 4) . Notably, silencing of caspase-2 again suppressed TRAIL-induced Bid cleavage in these cells (Fig. 4) . Based on these results, we propose that caspase-2 activity is required prior to Bid cleavage, whereas caspase-2 processing requires events downstream of Bax.
DISCUSSION
Caspase-2 has not generated the same amount of interest as other family members, such as caspase-3, -8, or -9, in part because caspase-2 knock-out mice lack a severe phenotype. Recent reports implicating caspase-2 in stress-induced apoptosis, however, have suggested that these extrapolations based on genetically engineered mice may have underestimated the role of caspase-2 in apoptosis (12) . In the present study, we found that caspase-2 is required for optimal TRAIL/Apo2L-induced cell death in certain type II cells. We show that downregulation of caspase-2 using RNA interference significantly inhibited TRAIL-induced apoptosis in HCT116 human colon and T3M4 pancreatic cancer cells but not in HeLa cervical carcinoma cell lines. The molecular basis for why some cells require caspase-2 but others do not is unclear. Notably, however, deficiency in caspase-9 or caspase-3 reportedly induces compensatory caspase activation (26) . Thus, the necessity of caspase-2 among cell types or populations may reflect distinct defects in apoptotic pathways arising during oncogenesis, which dictate the differential requirement for cell death components such as caspase-2.
Although Lassus et al. (12) reported a role for caspase-2 in DNA damage-induced apoptosis using similar reagents, downregulation of caspase-2 did not block etoposide-induced cell death in the cell lines we tested. Based on our results, however, the requirement for caspase-2 is clearly cell type-dependent, which may explain this discrepancy. Nevertheless, both studies point to a role for caspase-2 in the release of mitochondrial factors leading to the proteolytic processing of caspase-9 and the maturation of active caspase-3. Our data define that role in TRAIL-induced apoptosis, which implicates caspase-2 as necessary for optimal Bid cleavage in some type II cells. Consistent with these data, Alnemri and co-workers (13) found that caspase-2 engages the intrinsic apoptosis pathway by inducing the release of cytochrome c and other mitochondrial apoptogenic factors into the cell cytoplasm. Moreover, using in vitro assays, these investigators found that physiological levels of purified caspase-2 cleaved cytosolic Bid protein, which in turn triggered the release of cytochrome c from isolated mitochondria (13) . It should be noted, however, that our data do not address whether the role of caspase-2 in Bid processing is direct or indirect.
Caspase-2 processing reportedly can be blocked by the caspase-3 inhibitor DEVD-CHO or caspase-3, caspase-9, or Apaf-1 deficiency, which has led to the notion that caspase-2 FIG. 5 . Proposed model for the role of caspase-2 in the TRAILapoptosis pathway. TRAIL binding to DR4 and DR5 stimulates recruitment and activation of caspase-8 as documented previously. In parallel, TRAIL induces the activation of caspase-2, which, either directly or indirectly, facilitates optimal Bid cleavage. Active caspase-2 may be stabilized by interdomain cleavage that is dependent on autocatalytic activity or downstream executioner caspases, thus amplifying the TRAIL proteolytic signaling cascade. Speculatively, caspase-2 may be recruited to the DISC or an analogous complex following TRAIL stimulation. Recruitment may be facilitated by CARD-CARD domain interactions, such as those between caspase-2 and RAIDD, which also has a death domain known to facilitate recruitment to the DISC or to the CARD-containing DEFCAD protein, which has been reported to interact with caspase-2.
FIG. 3.
Caspase-2 is interconnected between caspase-8 activation and Bid cleavage. A, protein extracts from HCT116 cells that were transfected with control siRNA (siGL3), siCaspase-8, siCaspase-2, or siBid for 48 h and then subsequently treated for 1, 3, or 6 h with TRAIL (see under "Materials and Methods") were analyzed for caspase-3 activity as measured by the hydrolysis of DEVD-AFC (top) or on Western blots using antibodies specific for the indicated proteins (bottom). B, caspase-2 activity is required for Bid cleavage. Western blot analysis was performed to monitor the effect of the semipermeable caspase-2 inhibitor Z-VDVAD-fmk (100 M) on caspase-8 and Bid processing in HCT116 BaxϪ/Ϫ cells treated simultaneously with 500 ng/ml recombinant human TRAIL for 1, 3, and 6 h. functions downstream of the mitochondria and apoptosome formation (15) . Our results show that in TRAIL-treated cells, proteolytic cleavage of caspase-2 was not detected in cells with diminished Bid levels or in Bax-deficient HCT116 BaxϪ/Ϫ cells, which indeed places the processing of caspase-2 downstream of the mitochondria and activation of caspase-3. Silencing caspase-2 expression using siRNA or inhibition of its activity with Z-VDVAD-fmk, however, suppressed TRAIL-induced Bid cleavage and subsequent mitochondrial dependent events. Although these peptidyl-based caspase inhibitors lack absolute specificity, our data taken together support the idea that in some cell types caspase-2 is required for optimal Bid cleavage; however, caspase-2 proteolytic processing is dependent upon activities downstream of Bax (Fig. 5) . Nevertheless, caspase-2 interdomain cleavage may indeed play a significant physiological role, for example, in stabilization of the active form of caspase-2, which is a proposed mode of activation for initiator caspases (2, 27) . Thus, caspase-2 cleavage by downstream executioner caspases may facilitate a positive feedback mechanism (Fig. 5) .
As introduced above, two modes of caspase activation have been proposed (2) . For executioner caspases like caspase-3 and -7, an active site is generated by interdomain cleavage (2) . For initiator caspases like caspase-8 and -9, an active site is formed when inactive monomers are dimerized by macromolecular interactions, such as those organized in the DISC or in the apoptosome, and subsequent interdomain cleavage facilitates dimer stability (2) . Although the mechanism of caspase-2 activation is unclear, our data indicate that initially it is not activated by the executioner caspase mode of interdomain cleavage. Caspase-2 and caspase-9 are the only caspases containing a CARD domain, which at least for caspase-9 has been shown to facilitate its recruitment to the apoptosome. Similarly, it is possible that the caspase-2 mode of activation takes place through dimerization in macromolecular complexes, which might be facilitated by its CARD-CARD domain interactions, such as those reported with RAIDD (28) , which also contains a death domain (DD), or with the CARD-containing DEFCAP protein (29) . Consistent with this hypothesis are recent reports showing that caspase-2 is recruited to a large protein complex that contains neither cytochrome c nor Apaf-1 but is sufficient for caspase-2 activation (30). Importantly, caspase-2 activation did not require interdomain cleavage (30) .
In summary, we show for the first time that caspase-2 is involved in TRAIL-induced apoptosis in different human cancer cell lines. Mapping of the TRAIL-signaling pathway by Western blot analysis after siRNA-mediated silencing of caspase-8 and Bid revealed that caspase-2 is interconnected between caspase-8 activation and Bid cleavage. Moreover, we provide evidence that caspase-2 processing is not necessary for its role in Bid cleavage. Based on our observations, we propose that caspase-2 is another point of regulation in the TRAIL death receptor pathway in certain type II cells.
